DNA Script is a leading company in manufacturing de novo synthetic nucleic acids using enzymatic DNA synthesis (EDS) technology, aiming to accelerate innovation in life science and technology through the decentralization of rapid, on demand and high-quality DNA synthesis. The company operates with a significant global footprint, anchored by its dual headquarters in Le Kremlin-Bicêtre (Paris area), France, and South San Francisco, California, USA.
Cyborg Score Rationale
DNA Script has raised $299M, with Series C financing of $200 million, bringing the total amount raised to $315 million since its founding in 2014. The company has proprietary enzymatic synthesis technology and a commercialized platform (SYNTAX), but remains private with competitive enzymatic DNA synthesis market pressures.
Top Insights
DNA Script's technology features a novel biochemical process for nucleic acid synthesis based on the use of efficient enzymes to provide rapid production of important genomic experimental precursors, such as an oligonucleotide, enabling researchers to accelerate their experiments and development of new therapeutics.
GE Research selected DNA Script to join a collaboration working on a rapid response, mobile platform to develop on-demand production of nucleic acid-based vaccines and therapies related to biological threats.
DNA Script has 132 total employees.
The company supports a worldwide customer base through direct sales, service operations, and distribution partnerships across North America, Europe, and the Asia-Pacific region.
Named Competitors
Evonetix — Enzymatic DNA synthesis platform
Nuclera — On-demand DNA synthesis technology
Integrated DNA Technologies — DNA synthesis and genomic analysis tools
Oxford Nanopore Technologies — Nanopore sequencing and genomics
Eurofins Genomics — Contract genomic services and synthesis
Recent Developments
(2024 April) DNA Script sponsored DNA Day, a genomics science conference at Genopole in Évry-Courcouronnes
(2023 November) Launched new RNA synthesis kits for the SYNTAX Platform enabling on-demand production of custom single-guide RNA (sgRNA)
(2023 November) Appointed Don Kania, Ph.D. as new Chairman of Board of Directors
Open the full interactive DNA Script report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.